Global Biosimilars Treatment Market Insights, Forecast to 2029
This report presents an overview of global market for Biosimilars Treatment market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Biosimilars Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biosimilars Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biosimilars Treatment revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Biosimilars Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Biosimilars Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer, Eli Lily, Inc., Pfizer, Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Amgen Inc., Biocon, Dr. Reddy’s Laboratories and Roche Ltd., etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Biosimilars Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilars Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilars Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Biosimilars Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biosimilars Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biosimilars Treatment revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Biosimilars Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Biosimilars Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer, Eli Lily, Inc., Pfizer, Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Amgen Inc., Biocon, Dr. Reddy’s Laboratories and Roche Ltd., etc.
By Company
- Bayer
- Eli Lily, Inc.
- Pfizer, Inc.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Limited
- Amgen Inc.
- Biocon
- Dr. Reddy’s Laboratories
- Roche Ltd.
- Celltrion, Inc.
- Samsung Bioepis
- Recombinant Non – Glycosylated Proteins
- Recombinant Glycosylated Proteins
- Recombinant Peptides
- Oncology
- Chronic and Autoimmune Disease
- Blood Disorders
- Growth Hormone Disease
- Infectious Disease
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Biosimilars Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilars Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilars Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Recombinant Non – Glycosylated Proteins
1.2.3 Recombinant Glycosylated Proteins
1.2.4 Recombinant Peptides
1.3 Market by Application
1.3.1 Global Biosimilars Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Oncology
1.3.3 Chronic and Autoimmune Disease
1.3.4 Blood Disorders
1.3.5 Growth Hormone Disease
1.3.6 Infectious Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Biosimilars Treatment Market Perspective (2018-2029)
2.2 Global Biosimilars Treatment Growth Trends by Region
2.2.1 Biosimilars Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biosimilars Treatment Historic Market Size by Region (2018-2023)
2.2.3 Biosimilars Treatment Forecasted Market Size by Region (2024-2029)
2.3 Biosimilars Treatment Market Dynamics
2.3.1 Biosimilars Treatment Industry Trends
2.3.2 Biosimilars Treatment Market Drivers
2.3.3 Biosimilars Treatment Market Challenges
2.3.4 Biosimilars Treatment Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Biosimilars Treatment by Players
3.1.1 Global Biosimilars Treatment Revenue by Players (2018-2023)
3.1.2 Global Biosimilars Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Biosimilars Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Biosimilars Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Biosimilars Treatment Market Concentration Ratio
3.4.1 Global Biosimilars Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars Treatment Revenue in 2022
3.5 Global Key Players of Biosimilars Treatment Head office and Area Served
3.6 Global Key Players of Biosimilars Treatment, Product and Application
3.7 Global Key Players of Biosimilars Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 BIOSIMILARS TREATMENT BREAKDOWN DATA BY TYPE
4.1 Global Biosimilars Treatment Historic Market Size by Type (2018-2023)
4.2 Global Biosimilars Treatment Forecasted Market Size by Type (2024-2029)
5 BIOSIMILARS TREATMENT BREAKDOWN DATA BY APPLICATION
5.1 Global Biosimilars Treatment Historic Market Size by Application (2018-2023)
5.2 Global Biosimilars Treatment Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Biosimilars Treatment Market Size (2018-2029)
6.2 North America Biosimilars Treatment Market Size by Type
6.2.1 North America Biosimilars Treatment Market Size by Type (2018-2023)
6.2.2 North America Biosimilars Treatment Market Size by Type (2024-2029)
6.2.3 North America Biosimilars Treatment Market Share by Type (2018-2029)
6.3 North America Biosimilars Treatment Market Size by Application
6.3.1 North America Biosimilars Treatment Market Size by Application (2018-2023)
6.3.2 North America Biosimilars Treatment Market Size by Application (2024-2029)
6.3.3 North America Biosimilars Treatment Market Share by Application (2018-2029)
6.4 North America Biosimilars Treatment Market Size by Country
6.4.1 North America Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Biosimilars Treatment Market Size by Country (2018-2023)
6.4.3 North America Biosimilars Treatment Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 EUROPE
7.1 Europe Biosimilars Treatment Market Size (2018-2029)
7.2 Europe Biosimilars Treatment Market Size by Type
7.2.1 Europe Biosimilars Treatment Market Size by Type (2018-2023)
7.2.2 Europe Biosimilars Treatment Market Size by Type (2024-2029)
7.2.3 Europe Biosimilars Treatment Market Share by Type (2018-2029)
7.3 Europe Biosimilars Treatment Market Size by Application
7.3.1 Europe Biosimilars Treatment Market Size by Application (2018-2023)
7.3.2 Europe Biosimilars Treatment Market Size by Application (2024-2029)
7.3.3 Europe Biosimilars Treatment Market Share by Application (2018-2029)
7.4 Europe Biosimilars Treatment Market Size by Country
7.4.1 Europe Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Biosimilars Treatment Market Size by Country (2018-2023)
7.4.3 Europe Biosimilars Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Biosimilars Treatment Market Size (2018-2029)
8.2 China Biosimilars Treatment Market Size by Type
8.2.1 China Biosimilars Treatment Market Size by Type (2018-2023)
8.2.2 China Biosimilars Treatment Market Size by Type (2024-2029)
8.2.3 China Biosimilars Treatment Market Share by Type (2018-2029)
8.3 China Biosimilars Treatment Market Size by Application
8.3.1 China Biosimilars Treatment Market Size by Application (2018-2023)
8.3.2 China Biosimilars Treatment Market Size by Application (2024-2029)
8.3.3 China Biosimilars Treatment Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Biosimilars Treatment Market Size (2018-2029)
9.2 Asia Biosimilars Treatment Market Size by Type
9.2.1 Asia Biosimilars Treatment Market Size by Type (2018-2023)
9.2.2 Asia Biosimilars Treatment Market Size by Type (2024-2029)
9.2.3 Asia Biosimilars Treatment Market Share by Type (2018-2029)
9.3 Asia Biosimilars Treatment Market Size by Application
9.3.1 Asia Biosimilars Treatment Market Size by Application (2018-2023)
9.3.2 Asia Biosimilars Treatment Market Size by Application (2024-2029)
9.3.3 Asia Biosimilars Treatment Market Share by Application (2018-2029)
9.4 Asia Biosimilars Treatment Market Size by Region
9.4.1 Asia Biosimilars Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Biosimilars Treatment Market Size by Region (2018-2023)
9.4.3 Asia Biosimilars Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Biosimilars Treatment Introduction
11.1.4 Bayer Revenue in Biosimilars Treatment Business (2018-2023)
11.1.5 Bayer Recent Developments
11.2 Eli Lily, Inc.
11.2.1 Eli Lily, Inc. Company Details
11.2.2 Eli Lily, Inc. Business Overview
11.2.3 Eli Lily, Inc. Biosimilars Treatment Introduction
11.2.4 Eli Lily, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.2.5 Eli Lily, Inc. Recent Developments
11.3 Pfizer, Inc.
11.3.1 Pfizer, Inc. Company Details
11.3.2 Pfizer, Inc. Business Overview
11.3.3 Pfizer, Inc. Biosimilars Treatment Introduction
11.3.4 Pfizer, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.3.5 Pfizer, Inc. Recent Developments
11.4 Sandoz International GmbH
11.4.1 Sandoz International GmbH Company Details
11.4.2 Sandoz International GmbH Business Overview
11.4.3 Sandoz International GmbH Biosimilars Treatment Introduction
11.4.4 Sandoz International GmbH Revenue in Biosimilars Treatment Business (2018-2023)
11.4.5 Sandoz International GmbH Recent Developments
11.5 Teva Pharmaceutical Industries Limited
11.5.1 Teva Pharmaceutical Industries Limited Company Details
11.5.2 Teva Pharmaceutical Industries Limited Business Overview
11.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Limited Revenue in Biosimilars Treatment Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Limited Recent Developments
11.6 Amgen Inc.
11.6.1 Amgen Inc. Company Details
11.6.2 Amgen Inc. Business Overview
11.6.3 Amgen Inc. Biosimilars Treatment Introduction
11.6.4 Amgen Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.6.5 Amgen Inc. Recent Developments
11.7 Biocon
11.7.1 Biocon Company Details
11.7.2 Biocon Business Overview
11.7.3 Biocon Biosimilars Treatment Introduction
11.7.4 Biocon Revenue in Biosimilars Treatment Business (2018-2023)
11.7.5 Biocon Recent Developments
11.8 Dr. Reddy’s Laboratories
11.8.1 Dr. Reddy’s Laboratories Company Details
11.8.2 Dr. Reddy’s Laboratories Business Overview
11.8.3 Dr. Reddy’s Laboratories Biosimilars Treatment Introduction
11.8.4 Dr. Reddy’s Laboratories Revenue in Biosimilars Treatment Business (2018-2023)
11.8.5 Dr. Reddy’s Laboratories Recent Developments
11.9 Roche Ltd.
11.9.1 Roche Ltd. Company Details
11.9.2 Roche Ltd. Business Overview
11.9.3 Roche Ltd. Biosimilars Treatment Introduction
11.9.4 Roche Ltd. Revenue in Biosimilars Treatment Business (2018-2023)
11.9.5 Roche Ltd. Recent Developments
11.10 Celltrion, Inc.
11.10.1 Celltrion, Inc. Company Details
11.10.2 Celltrion, Inc. Business Overview
11.10.3 Celltrion, Inc. Biosimilars Treatment Introduction
11.10.4 Celltrion, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.10.5 Celltrion, Inc. Recent Developments
11.11 Samsung Bioepis
11.11.1 Samsung Bioepis Company Details
11.11.2 Samsung Bioepis Business Overview
11.11.3 Samsung Bioepis Biosimilars Treatment Introduction
11.11.4 Samsung Bioepis Revenue in Biosimilars Treatment Business (2018-2023)
11.11.5 Samsung Bioepis Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Recombinant Non – Glycosylated Proteins
1.2.3 Recombinant Glycosylated Proteins
1.2.4 Recombinant Peptides
1.3 Market by Application
1.3.1 Global Biosimilars Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Oncology
1.3.3 Chronic and Autoimmune Disease
1.3.4 Blood Disorders
1.3.5 Growth Hormone Disease
1.3.6 Infectious Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Biosimilars Treatment Market Perspective (2018-2029)
2.2 Global Biosimilars Treatment Growth Trends by Region
2.2.1 Biosimilars Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biosimilars Treatment Historic Market Size by Region (2018-2023)
2.2.3 Biosimilars Treatment Forecasted Market Size by Region (2024-2029)
2.3 Biosimilars Treatment Market Dynamics
2.3.1 Biosimilars Treatment Industry Trends
2.3.2 Biosimilars Treatment Market Drivers
2.3.3 Biosimilars Treatment Market Challenges
2.3.4 Biosimilars Treatment Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Biosimilars Treatment by Players
3.1.1 Global Biosimilars Treatment Revenue by Players (2018-2023)
3.1.2 Global Biosimilars Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Biosimilars Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Biosimilars Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Biosimilars Treatment Market Concentration Ratio
3.4.1 Global Biosimilars Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars Treatment Revenue in 2022
3.5 Global Key Players of Biosimilars Treatment Head office and Area Served
3.6 Global Key Players of Biosimilars Treatment, Product and Application
3.7 Global Key Players of Biosimilars Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 BIOSIMILARS TREATMENT BREAKDOWN DATA BY TYPE
4.1 Global Biosimilars Treatment Historic Market Size by Type (2018-2023)
4.2 Global Biosimilars Treatment Forecasted Market Size by Type (2024-2029)
5 BIOSIMILARS TREATMENT BREAKDOWN DATA BY APPLICATION
5.1 Global Biosimilars Treatment Historic Market Size by Application (2018-2023)
5.2 Global Biosimilars Treatment Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Biosimilars Treatment Market Size (2018-2029)
6.2 North America Biosimilars Treatment Market Size by Type
6.2.1 North America Biosimilars Treatment Market Size by Type (2018-2023)
6.2.2 North America Biosimilars Treatment Market Size by Type (2024-2029)
6.2.3 North America Biosimilars Treatment Market Share by Type (2018-2029)
6.3 North America Biosimilars Treatment Market Size by Application
6.3.1 North America Biosimilars Treatment Market Size by Application (2018-2023)
6.3.2 North America Biosimilars Treatment Market Size by Application (2024-2029)
6.3.3 North America Biosimilars Treatment Market Share by Application (2018-2029)
6.4 North America Biosimilars Treatment Market Size by Country
6.4.1 North America Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Biosimilars Treatment Market Size by Country (2018-2023)
6.4.3 North America Biosimilars Treatment Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 EUROPE
7.1 Europe Biosimilars Treatment Market Size (2018-2029)
7.2 Europe Biosimilars Treatment Market Size by Type
7.2.1 Europe Biosimilars Treatment Market Size by Type (2018-2023)
7.2.2 Europe Biosimilars Treatment Market Size by Type (2024-2029)
7.2.3 Europe Biosimilars Treatment Market Share by Type (2018-2029)
7.3 Europe Biosimilars Treatment Market Size by Application
7.3.1 Europe Biosimilars Treatment Market Size by Application (2018-2023)
7.3.2 Europe Biosimilars Treatment Market Size by Application (2024-2029)
7.3.3 Europe Biosimilars Treatment Market Share by Application (2018-2029)
7.4 Europe Biosimilars Treatment Market Size by Country
7.4.1 Europe Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Biosimilars Treatment Market Size by Country (2018-2023)
7.4.3 Europe Biosimilars Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Biosimilars Treatment Market Size (2018-2029)
8.2 China Biosimilars Treatment Market Size by Type
8.2.1 China Biosimilars Treatment Market Size by Type (2018-2023)
8.2.2 China Biosimilars Treatment Market Size by Type (2024-2029)
8.2.3 China Biosimilars Treatment Market Share by Type (2018-2029)
8.3 China Biosimilars Treatment Market Size by Application
8.3.1 China Biosimilars Treatment Market Size by Application (2018-2023)
8.3.2 China Biosimilars Treatment Market Size by Application (2024-2029)
8.3.3 China Biosimilars Treatment Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Biosimilars Treatment Market Size (2018-2029)
9.2 Asia Biosimilars Treatment Market Size by Type
9.2.1 Asia Biosimilars Treatment Market Size by Type (2018-2023)
9.2.2 Asia Biosimilars Treatment Market Size by Type (2024-2029)
9.2.3 Asia Biosimilars Treatment Market Share by Type (2018-2029)
9.3 Asia Biosimilars Treatment Market Size by Application
9.3.1 Asia Biosimilars Treatment Market Size by Application (2018-2023)
9.3.2 Asia Biosimilars Treatment Market Size by Application (2024-2029)
9.3.3 Asia Biosimilars Treatment Market Share by Application (2018-2029)
9.4 Asia Biosimilars Treatment Market Size by Region
9.4.1 Asia Biosimilars Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Biosimilars Treatment Market Size by Region (2018-2023)
9.4.3 Asia Biosimilars Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Biosimilars Treatment Introduction
11.1.4 Bayer Revenue in Biosimilars Treatment Business (2018-2023)
11.1.5 Bayer Recent Developments
11.2 Eli Lily, Inc.
11.2.1 Eli Lily, Inc. Company Details
11.2.2 Eli Lily, Inc. Business Overview
11.2.3 Eli Lily, Inc. Biosimilars Treatment Introduction
11.2.4 Eli Lily, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.2.5 Eli Lily, Inc. Recent Developments
11.3 Pfizer, Inc.
11.3.1 Pfizer, Inc. Company Details
11.3.2 Pfizer, Inc. Business Overview
11.3.3 Pfizer, Inc. Biosimilars Treatment Introduction
11.3.4 Pfizer, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.3.5 Pfizer, Inc. Recent Developments
11.4 Sandoz International GmbH
11.4.1 Sandoz International GmbH Company Details
11.4.2 Sandoz International GmbH Business Overview
11.4.3 Sandoz International GmbH Biosimilars Treatment Introduction
11.4.4 Sandoz International GmbH Revenue in Biosimilars Treatment Business (2018-2023)
11.4.5 Sandoz International GmbH Recent Developments
11.5 Teva Pharmaceutical Industries Limited
11.5.1 Teva Pharmaceutical Industries Limited Company Details
11.5.2 Teva Pharmaceutical Industries Limited Business Overview
11.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Limited Revenue in Biosimilars Treatment Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Limited Recent Developments
11.6 Amgen Inc.
11.6.1 Amgen Inc. Company Details
11.6.2 Amgen Inc. Business Overview
11.6.3 Amgen Inc. Biosimilars Treatment Introduction
11.6.4 Amgen Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.6.5 Amgen Inc. Recent Developments
11.7 Biocon
11.7.1 Biocon Company Details
11.7.2 Biocon Business Overview
11.7.3 Biocon Biosimilars Treatment Introduction
11.7.4 Biocon Revenue in Biosimilars Treatment Business (2018-2023)
11.7.5 Biocon Recent Developments
11.8 Dr. Reddy’s Laboratories
11.8.1 Dr. Reddy’s Laboratories Company Details
11.8.2 Dr. Reddy’s Laboratories Business Overview
11.8.3 Dr. Reddy’s Laboratories Biosimilars Treatment Introduction
11.8.4 Dr. Reddy’s Laboratories Revenue in Biosimilars Treatment Business (2018-2023)
11.8.5 Dr. Reddy’s Laboratories Recent Developments
11.9 Roche Ltd.
11.9.1 Roche Ltd. Company Details
11.9.2 Roche Ltd. Business Overview
11.9.3 Roche Ltd. Biosimilars Treatment Introduction
11.9.4 Roche Ltd. Revenue in Biosimilars Treatment Business (2018-2023)
11.9.5 Roche Ltd. Recent Developments
11.10 Celltrion, Inc.
11.10.1 Celltrion, Inc. Company Details
11.10.2 Celltrion, Inc. Business Overview
11.10.3 Celltrion, Inc. Biosimilars Treatment Introduction
11.10.4 Celltrion, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.10.5 Celltrion, Inc. Recent Developments
11.11 Samsung Bioepis
11.11.1 Samsung Bioepis Company Details
11.11.2 Samsung Bioepis Business Overview
11.11.3 Samsung Bioepis Biosimilars Treatment Introduction
11.11.4 Samsung Bioepis Revenue in Biosimilars Treatment Business (2018-2023)
11.11.5 Samsung Bioepis Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Biosimilars Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Recombinant Non – Glycosylated Proteins
Table 3. Key Players of Recombinant Glycosylated Proteins
Table 4. Key Players of Recombinant Peptides
Table 5. Global Biosimilars Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 6. Global Biosimilars Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Biosimilars Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Biosimilars Treatment Market Share by Region (2018-2023)
Table 9. Global Biosimilars Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Biosimilars Treatment Market Share by Region (2024-2029)
Table 11. Biosimilars Treatment Market Trends
Table 12. Biosimilars Treatment Market Drivers
Table 13. Biosimilars Treatment Market Challenges
Table 14. Biosimilars Treatment Market Restraints
Table 15. Global Biosimilars Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Biosimilars Treatment Revenue Share by Players (2018-2023)
Table 17. Global Top Biosimilars Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2022)
Table 18. Global Biosimilars Treatment Industry Ranking 2021 VS 2022 VS 2023
Table 19. Global 5 Largest Players Market Share by Biosimilars Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 20. Global Key Players of Biosimilars Treatment, Headquarters and Area Served
Table 21. Global Key Players of Biosimilars Treatment, Product and Application
Table 22. Global Key Players of Biosimilars Treatment, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Biosimilars Treatment Revenue Market Share by Type (2018-2023)
Table 26. Global Biosimilars Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Biosimilars Treatment Revenue Market Share by Type (2024-2029)
Table 28. Global Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Biosimilars Treatment Revenue Share by Application (2018-2023)
Table 30. Global Biosimilars Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Biosimilars Treatment Revenue Share by Application (2024-2029)
Table 32. North America Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 33. North America Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 34. North America Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 35. North America Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 36. North America Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Biosimilars Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 40. Europe Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 41. Europe Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 42. Europe Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 43. Europe Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Europe Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 45. Europe Biosimilars Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 46. China Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 47. China Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 48. China Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 49. China Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 50. Asia Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 51. Asia Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 52. Asia Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 53. Asia Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 54. Asia Biosimilars Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 55. Asia Biosimilars Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 56. Asia Biosimilars Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 62. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 64. Bayer Company Details
Table 65. Bayer Business Overview
Table 66. Bayer Biosimilars Treatment Product
Table 67. Bayer Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 68. Bayer Recent Developments
Table 69. Eli Lily, Inc. Company Details
Table 70. Eli Lily, Inc. Business Overview
Table 71. Eli Lily, Inc. Biosimilars Treatment Product
Table 72. Eli Lily, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 73. Eli Lily, Inc. Recent Developments
Table 74. Pfizer, Inc. Company Details
Table 75. Pfizer, Inc. Business Overview
Table 76. Pfizer, Inc. Biosimilars Treatment Product
Table 77. Pfizer, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 78. Pfizer, Inc. Recent Developments
Table 79. Sandoz International GmbH Company Details
Table 80. Sandoz International GmbH Business Overview
Table 81. Sandoz International GmbH Biosimilars Treatment Product
Table 82. Sandoz International GmbH Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 83. Sandoz International GmbH Recent Developments
Table 84. Teva Pharmaceutical Industries Limited Company Details
Table 85. Teva Pharmaceutical Industries Limited Business Overview
Table 86. Teva Pharmaceutical Industries Limited Biosimilars Treatment Product
Table 87. Teva Pharmaceutical Industries Limited Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 88. Teva Pharmaceutical Industries Limited Recent Developments
Table 89. Amgen Inc. Company Details
Table 90. Amgen Inc. Business Overview
Table 91. Amgen Inc. Biosimilars Treatment Product
Table 92. Amgen Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 93. Amgen Inc. Recent Developments
Table 94. Biocon Company Details
Table 95. Biocon Business Overview
Table 96. Biocon Biosimilars Treatment Product
Table 97. Biocon Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 98. Biocon Recent Developments
Table 99. Dr. Reddy’s Laboratories Company Details
Table 100. Dr. Reddy’s Laboratories Business Overview
Table 101. Dr. Reddy’s Laboratories Biosimilars Treatment Product
Table 102. Dr. Reddy’s Laboratories Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 103. Dr. Reddy’s Laboratories Recent Developments
Table 104. Roche Ltd. Company Details
Table 105. Roche Ltd. Business Overview
Table 106. Roche Ltd. Biosimilars Treatment Product
Table 107. Roche Ltd. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 108. Roche Ltd. Recent Developments
Table 109. Celltrion, Inc. Company Details
Table 110. Celltrion, Inc. Business Overview
Table 111. Celltrion, Inc. Biosimilars Treatment Product
Table 112. Celltrion, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 113. Celltrion, Inc. Recent Developments
Table 114. Samsung Bioepis Company Details
Table 115. Samsung Bioepis Business Overview
Table 116. Samsung Bioepis Biosimilars Treatment Product
Table 117. Samsung Bioepis Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 118. Samsung Bioepis Recent Developments
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
Table 1. Global Biosimilars Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Recombinant Non – Glycosylated Proteins
Table 3. Key Players of Recombinant Glycosylated Proteins
Table 4. Key Players of Recombinant Peptides
Table 5. Global Biosimilars Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 6. Global Biosimilars Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Biosimilars Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Biosimilars Treatment Market Share by Region (2018-2023)
Table 9. Global Biosimilars Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Biosimilars Treatment Market Share by Region (2024-2029)
Table 11. Biosimilars Treatment Market Trends
Table 12. Biosimilars Treatment Market Drivers
Table 13. Biosimilars Treatment Market Challenges
Table 14. Biosimilars Treatment Market Restraints
Table 15. Global Biosimilars Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Biosimilars Treatment Revenue Share by Players (2018-2023)
Table 17. Global Top Biosimilars Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2022)
Table 18. Global Biosimilars Treatment Industry Ranking 2021 VS 2022 VS 2023
Table 19. Global 5 Largest Players Market Share by Biosimilars Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 20. Global Key Players of Biosimilars Treatment, Headquarters and Area Served
Table 21. Global Key Players of Biosimilars Treatment, Product and Application
Table 22. Global Key Players of Biosimilars Treatment, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Biosimilars Treatment Revenue Market Share by Type (2018-2023)
Table 26. Global Biosimilars Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Biosimilars Treatment Revenue Market Share by Type (2024-2029)
Table 28. Global Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Biosimilars Treatment Revenue Share by Application (2018-2023)
Table 30. Global Biosimilars Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Biosimilars Treatment Revenue Share by Application (2024-2029)
Table 32. North America Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 33. North America Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 34. North America Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 35. North America Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 36. North America Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Biosimilars Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 40. Europe Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 41. Europe Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 42. Europe Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 43. Europe Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Europe Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 45. Europe Biosimilars Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 46. China Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 47. China Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 48. China Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 49. China Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 50. Asia Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 51. Asia Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 52. Asia Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 53. Asia Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 54. Asia Biosimilars Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 55. Asia Biosimilars Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 56. Asia Biosimilars Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 62. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 64. Bayer Company Details
Table 65. Bayer Business Overview
Table 66. Bayer Biosimilars Treatment Product
Table 67. Bayer Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 68. Bayer Recent Developments
Table 69. Eli Lily, Inc. Company Details
Table 70. Eli Lily, Inc. Business Overview
Table 71. Eli Lily, Inc. Biosimilars Treatment Product
Table 72. Eli Lily, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 73. Eli Lily, Inc. Recent Developments
Table 74. Pfizer, Inc. Company Details
Table 75. Pfizer, Inc. Business Overview
Table 76. Pfizer, Inc. Biosimilars Treatment Product
Table 77. Pfizer, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 78. Pfizer, Inc. Recent Developments
Table 79. Sandoz International GmbH Company Details
Table 80. Sandoz International GmbH Business Overview
Table 81. Sandoz International GmbH Biosimilars Treatment Product
Table 82. Sandoz International GmbH Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 83. Sandoz International GmbH Recent Developments
Table 84. Teva Pharmaceutical Industries Limited Company Details
Table 85. Teva Pharmaceutical Industries Limited Business Overview
Table 86. Teva Pharmaceutical Industries Limited Biosimilars Treatment Product
Table 87. Teva Pharmaceutical Industries Limited Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 88. Teva Pharmaceutical Industries Limited Recent Developments
Table 89. Amgen Inc. Company Details
Table 90. Amgen Inc. Business Overview
Table 91. Amgen Inc. Biosimilars Treatment Product
Table 92. Amgen Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 93. Amgen Inc. Recent Developments
Table 94. Biocon Company Details
Table 95. Biocon Business Overview
Table 96. Biocon Biosimilars Treatment Product
Table 97. Biocon Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 98. Biocon Recent Developments
Table 99. Dr. Reddy’s Laboratories Company Details
Table 100. Dr. Reddy’s Laboratories Business Overview
Table 101. Dr. Reddy’s Laboratories Biosimilars Treatment Product
Table 102. Dr. Reddy’s Laboratories Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 103. Dr. Reddy’s Laboratories Recent Developments
Table 104. Roche Ltd. Company Details
Table 105. Roche Ltd. Business Overview
Table 106. Roche Ltd. Biosimilars Treatment Product
Table 107. Roche Ltd. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 108. Roche Ltd. Recent Developments
Table 109. Celltrion, Inc. Company Details
Table 110. Celltrion, Inc. Business Overview
Table 111. Celltrion, Inc. Biosimilars Treatment Product
Table 112. Celltrion, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 113. Celltrion, Inc. Recent Developments
Table 114. Samsung Bioepis Company Details
Table 115. Samsung Bioepis Business Overview
Table 116. Samsung Bioepis Biosimilars Treatment Product
Table 117. Samsung Bioepis Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 118. Samsung Bioepis Recent Developments
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Biosimilars Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Biosimilars Treatment Market Share by Type: 2022 VS 2029
Figure 3. Recombinant Non – Glycosylated Proteins Features
Figure 4. Recombinant Glycosylated Proteins Features
Figure 5. Recombinant Peptides Features
Figure 6. Global Biosimilars Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Biosimilars Treatment Market Share by Application: 2022 VS 2029
Figure 8. Oncology Case Studies
Figure 9. Chronic and Autoimmune Disease Case Studies
Figure 10. Blood Disorders Case Studies
Figure 11. Growth Hormone Disease Case Studies
Figure 12. Infectious Disease Case Studies
Figure 13. Biosimilars Treatment Report Years Considered
Figure 14. Global Biosimilars Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Biosimilars Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Biosimilars Treatment Market Share by Region: 2022 VS 2029
Figure 17. Global Biosimilars Treatment Market Share by Players in 2022
Figure 18. Global Top Biosimilars Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Biosimilars Treatment Revenue in 2022
Figure 20. North America Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Biosimilars Treatment Market Share by Type (2018-2029)
Figure 22. North America Biosimilars Treatment Market Share by Application (2018-2029)
Figure 23. North America Biosimilars Treatment Market Share by Country (2018-2029)
Figure 24. United States Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Biosimilars Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Biosimilars Treatment Market Share by Type (2018-2029)
Figure 28. Europe Biosimilars Treatment Market Share by Application (2018-2029)
Figure 29. Europe Biosimilars Treatment Market Share by Country (2018-2029)
Figure 30. Germany Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Biosimilars Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Biosimilars Treatment Market Share by Type (2018-2029)
Figure 38. China Biosimilars Treatment Market Share by Application (2018-2029)
Figure 39. Asia Biosimilars Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Biosimilars Treatment Market Share by Type (2018-2029)
Figure 41. Asia Biosimilars Treatment Market Share by Application (2018-2029)
Figure 42. Asia Biosimilars Treatment Market Share by Region (2018-2029)
Figure 43. Japan Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Biosimilars Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Country (2018-2029)
Figure 53. Brazil Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Bayer Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 60. Eli Lily, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 61. Pfizer, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 62. Sandoz International GmbH Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 63. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 64. Amgen Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 65. Biocon Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 66. Dr. Reddy’s Laboratories Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 67. Roche Ltd. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 68. Celltrion, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 69. Samsung Bioepis Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Figure 1. Global Biosimilars Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Biosimilars Treatment Market Share by Type: 2022 VS 2029
Figure 3. Recombinant Non – Glycosylated Proteins Features
Figure 4. Recombinant Glycosylated Proteins Features
Figure 5. Recombinant Peptides Features
Figure 6. Global Biosimilars Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Biosimilars Treatment Market Share by Application: 2022 VS 2029
Figure 8. Oncology Case Studies
Figure 9. Chronic and Autoimmune Disease Case Studies
Figure 10. Blood Disorders Case Studies
Figure 11. Growth Hormone Disease Case Studies
Figure 12. Infectious Disease Case Studies
Figure 13. Biosimilars Treatment Report Years Considered
Figure 14. Global Biosimilars Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Biosimilars Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Biosimilars Treatment Market Share by Region: 2022 VS 2029
Figure 17. Global Biosimilars Treatment Market Share by Players in 2022
Figure 18. Global Top Biosimilars Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Biosimilars Treatment Revenue in 2022
Figure 20. North America Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Biosimilars Treatment Market Share by Type (2018-2029)
Figure 22. North America Biosimilars Treatment Market Share by Application (2018-2029)
Figure 23. North America Biosimilars Treatment Market Share by Country (2018-2029)
Figure 24. United States Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Biosimilars Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Biosimilars Treatment Market Share by Type (2018-2029)
Figure 28. Europe Biosimilars Treatment Market Share by Application (2018-2029)
Figure 29. Europe Biosimilars Treatment Market Share by Country (2018-2029)
Figure 30. Germany Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Biosimilars Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Biosimilars Treatment Market Share by Type (2018-2029)
Figure 38. China Biosimilars Treatment Market Share by Application (2018-2029)
Figure 39. Asia Biosimilars Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Biosimilars Treatment Market Share by Type (2018-2029)
Figure 41. Asia Biosimilars Treatment Market Share by Application (2018-2029)
Figure 42. Asia Biosimilars Treatment Market Share by Region (2018-2029)
Figure 43. Japan Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Biosimilars Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Country (2018-2029)
Figure 53. Brazil Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Biosimilars Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Bayer Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 60. Eli Lily, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 61. Pfizer, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 62. Sandoz International GmbH Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 63. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 64. Amgen Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 65. Biocon Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 66. Dr. Reddy’s Laboratories Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 67. Roche Ltd. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 68. Celltrion, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 69. Samsung Bioepis Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
